ClinicalTrials.gg
CompletedNCT06394687Updated Oct 20, 2026

The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule

An interventional study of Milk Protein Concentrate and Micellar Casein Isolate in Amino Acid Change, Food Science and Nutrition, sponsored by Nimble Science Ltd.. Completed at 1 site in Canada. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Nimble Science Ltd. · Not applicable, Interventional, and Basic science

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

This study aims to understand how the Milk Protein Concentrate/Fast Protein (MCP/FP) investigational product (IP) compares to a control the Micellar Casein Isolate/Slow Protein (MCI/SP) product in healthy volunteers. It involves two phases where participants will try both products. The main goal is to measure the type and rate of amino acids quickly in the small intestine after consuming the protein products and how this relates to gastric emptying.

Read the detailed description

This study aims to compare how MPC and MCI are digested on their journey to the colon, and how the proteins are digested once in colon. Traditional methods for sampling the small intestine have limitations, so a new capsule technology will be used for non-invasive sampling.

Understanding how protein supplements like MPC and MCI are digested is crucial for determining their effectiveness and suitability for various purposes. By comparing these two types of supplements, one can gain insights into their unique digestion profiles and how they interact with the body. Additionally, analyzing how these supplements affect blood amino acid levels and stool profiles can offer further insights into their impact on the body's metabolism and gut health.

To collect samples from the small intestine, the SIMBA Capsule (designed by Nimble Science Ltd) will be used. This device offers a simple, non-invasive, and painless alternative to obtain a sample of the small intestine, suitable for laboratory analysis. The SIMBA capsule consists of a small pill sized container within a specially coated shell and is the size of capsules available in the market for food supplements such as fish oils. When swallowed, the capsule's coated shell (which resists the acidic stomach and dissolves in the small intestine) will pass through the stomach into the small intestine. Once the shell is dissolved, the capsule can collect a fluid sample from the small intestine through the designed openings that are now exposed. Additionally, the small intestinal fluid softens a latch on a spring-loaded plunger which leads to closing the openings and sealing the sampled fluid contents within the container.

In addition, there is the LIMBA capsule, which is functionally similar to the SIMBA capsule. The only difference is that the coating of the LIMBA capsule takes longer to dissolve. This allows the LIMBA capsule to collect samples from the large intestine. The coating has no effect on the rate the capsule is expelled.

By using technology like the SIMBA/LIMBA capsule for non-invasive sampling, one can overcome the limitations of traditional methods and obtain more accurate data on the digestion of these protein supplements. This will enable one to make informed recommendations regarding their usage and potentially identify novel applications for these products in clinical and nutritional settings. Ultimately, this study aims to enhance one's understanding of protein supplement metabolism and provide evidence-based guidance for individuals seeking to optimize their dietary intake for better health outcomes.

02

Conditions studied

  • Amino Acid Change
  • Food Science
  • Nutrition
  • Digestion Rate
  • Microtia

Browse trials for

Keywords

  • Mircobiome
03

In context

Congenital Microtia

33 studies on the registry are indexed under Congenital Microtia; 10 are open to participants now.

This study's enrollment of 24 is below the median of 34 across 23 interventional studies indexed under Congenital Microtia.

Browse Congenital Microtia studies →

Lead sponsor

Nimble Science Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 20 to 55 years old at inclusion in the study, both female and male subjects.
  2. Signed ; willing \& able to comply with study procedures.
  3. Willing to maintain their diet and physical activity levels during the study.
  4. Able to swallow a size-00 capsule (23mm length).
  5. No planned change in diet or medical interventions during the study duration

Exclusion criteria

Exclusion Criteria:

  1. Use of regular prescription medications, including antihypertensives, anti-inflammatory drugs, , , antidepressants, antipsychotics, anti-diabetic medications, and anti-arrhythmic agents, which in the opinion of the investigator, would adversely affect study safety or outcome.
  2. Prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, cancer diagnosis or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable.
  3. History of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction.
  4. Known history abdominal radiation treatment.
  5. Use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, GLP-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the study visit. Proton pump inhibitors (PPIs) are allowed provided a of 48 hours is respected before swallowing the SIMBA/LIMBA capsules and PPI treatment is resumed only 4 hours thereafter.
  6. Organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, Ogilvie's syndrome.
  7. Any significant gastrointestinal, heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome.
  8. Cancer diagnosis or treatment within the past year (non-melanoma skin cancers are acceptable).
  9. History or diagnosis of immunological or infectious disease (hepatitis, tuberculosis, , Parkinson's).
  10. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration.
  11. Antibiotic use (except for topical use) ≤ 12 weeks prior to screening. Potential participants may be eligible once a 12-week washout is completed.
  12. Consumption of probiotic or prebiotic supplements within 1 month prior to screening. Potential participants may be eligible once a 1-month washout is completed.
  13. Any prior Fecal Microbiota Transplantation.
  14. Colon cleanses/bowel prep for 2 weeks
  15. Pregnant or breastfeeding.
  16. Planning to become pregnant.
  17. Alcohol or drug abuse.
  18. Milk or soy allergy
  19. Lactose intolerant
  20. Vegan diet
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    MPC/FP to MCI/SP

    Participants ingest the MPC/FP protein product for their first intervention period, then MCI/SP for their second intervention period.

    Dietary Supplement: Milk Protein Concentrate · Dietary Supplement: Micellar Casein Isolate

  • Active comparator
    MCI/SP to MPC/FP

    Participants ingest the MCI/SP protein product for their first intervention period, then MPC/FP for their second intervention period.

    Dietary Supplement: Milk Protein Concentrate · Dietary Supplement: Micellar Casein Isolate

Interventions

  • Dietary supplementMilk Protein Concentrate

    Milk Protein Concentrate is a powdered dairy product made by removing most of the water from milk and contains a protein content below 90% on a dry matter basis. The product has been modified where some of the colloidal calcium phosphate component is reduced, which results in the dissociation of some of casein micelles, forming loose sub-micelle structures. This change modifies the digestion behaviour to be significantly faster.

    Also known as: Fast Protein

  • Dietary supplementMicellar Casein Isolate

    Micellar casein isolate is a type of protein supplement derived from milk. It belongs to the casein family of proteins, which includes various forms such as micellar casein, casein hydrolysate, and caseinates. During digestion micellar casein coagulates with both gastric acidification and enzymatic hydrolysis by pepsin, forming large stable curds which slow gastric emptying and provide a slower absorption of amino acids over time.

    Also known as: Slow Protein

06

What researchers measure

Primary outcomes

  1. Time to presentation of the peptides in the small intestine by SIMBA/LIMBA capsule

    Time to presentation of IP or Control peptides to the small intestine compared within subjects, measured by proteomic analysis from SIMBA/LIMBA capsules located in the small intestine based on X-ray confirmation. eg. T-90 min IP vs T-90 min Control, T-60 min IP vs T-60 min Control, etc),

    Time frame: From 0 minute to 240 minutes after ingestion of the capsule per intervention period

Secondary outcomes

  1. Time to presentation of the peptides in the small intestine by blood analysis

    Time to presentation of IP or Control peptides to the small intestine compared within subjects, measured by total amino acid analysis from blood samples difference in small intestinal proteomic profile between IP and Control phases based on PCA plot. (Maximum difference is defined by comparing the various SIMBA/LIMBA capsules within each patient, eg. T-90 min IP vs T-90 min Control, T-60 min IP vs T-60 min Control, etc),

    Time frame: From 0 minute to 240 minutes after ingestion of the protein product

  2. Determination of peptide composition

    The composition of milk-derived peptides by proteomic analysis. Statistical and mathematical analyses be employed to characterize the peptide profiles.

    Time frame: From 0 minute to 240 minutes after ingestion of the protein product per intervention period

  3. Determination of proteolysis rate

    The rate of milk-derived peptide proteolysis, gastric emptying, and nutrient absorption of IP or Control peptides. Statistical and mathematical analyses be employed to discern correlations and causative relationships among these processes.

    Time frame: From 0 minute to 240 minutes after ingestion of the protein product per intervention period

  4. Determination of metabolites from various samples

    The presence of the milk-derived peptide metabolites in small intestine, feces, and blood samples, following the IP or control intervention. Method of analysis being metabolomic technology.

    Time frame: From 0 minute to 240 minutes after ingestion of the capsule per intervention period

  5. Characterization of microbiota composition by metagenomic analysis

    Qualitative investigation of gut bacteria participation in the metabolism of dietary proteins, influencing the breakdown of peptides and amino acids during digestion, based on microbiome profiles compared across subjects.

    Time frame: From 0 minute to 240 minutes after ingestion of the capsule per intervention period

07

Study locations

1 site
  • Cumming School of Medicine
    Calgary, Alberta T2N 4N1, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in May 2025, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2025 → May 2025 and completion Jun 2025 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2024
First posted
May 1, 2024
StartActual
Nov 10, 2024
Primary completionActual
May 29, 2025was Jun 2025
CompletionActual
May 29, 2025was Jun 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Primary completion
Jun 12, 2025→May 29, 2025 (actual)
Oct 20, 2026
Study completion
Jun 12, 2025→May 29, 2025 (actual)
Oct 20, 2026
Enrollment
20 (estimated)→24 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    Primary completion Jun 12, 2025→May 29, 2025 (now actual)
    Study completion Jun 12, 2025→May 29, 2025 (now actual)
    Enrollment 20 (estimated)→24 (actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06394687
Lead sponsor
Nimble Science Ltd.
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Nov 10, 2024
Primary completion
May 29, 2025
Completion
May 29, 2025
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milk protein concentrate

Start the discussion